Date: 2015-08-07
Type of information: Nomination
Compound:
Company: Paion (Germany)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On August 7, 2015, Paion announced the appointment of Timothy E. Morris to the non-executive Board of Paion, Inc. where he will also serve as a financial advisor to the company. Tim Morris has 31 years of professional finance and accounting experience, 20 of those years spent in the role of Chief Financial Officer, predominantly with biopharmaceutical companies. Tim Morris will advise Paion, Inc. in building up and financing of the company\'s growing U.S. activities and in preparing for the upcoming commercialization of remimazolam. Tim Morris joined AcelRx Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, in 2014 and currently serves as its Chief Financial Officer and head of business development. Prior to AcelRx he served as a Chief Financial Officer, Senior Vice President finance and global corporate development of Vivus, from November 2004 to December 2013, overseeing finance, corporate development, IT, human resources, legal and investor relations functions. Prior to Vivus, Tim Morris was Chief Financial Officer, Senior Vice President finance, manufacturing and administration from September 2001 to November 2004, and was a member of the Office of the President from August 2004 to November 2004 for Questcor Pharmaceuticals, Inc. Tim Morris graduated cum laude with a bachelor of science in business with emphasis in accounting from California State University, Chico, and is a Certified Public Accountant.
Financial terms:
Latest news:
